硝苯地平与含利托那韦抗病毒方案的相互作用:PBPK/PD分析
本研究基于Simcyp硝苯地平模型建立三种剂型的PBPK/PD模型并经文献数据验证,模拟利托那韦对硝苯地平暴露及收缩压的影响。结果显示利托那韦强抑制CYP3A4使硝苯地平Cmax升高17.92–48.85倍、AUC升高63.30–84.01倍,收缩压降低>40 mmHg,可能致严重低血压,故不建议两方案同时使用。
要点
- 利托那韦强抑制CYP3A4,使硝苯地平Cmax升高17.92–48.85倍、AUC升高63.30–84.01倍。
- 合用可使收缩压降低>40 mmHg,存在严重低血压风险。
- 不建议患者同时使用含硝苯地平和含利托那韦的方案。
核心结论
- 利托那韦显著影响硝苯地平的药代动力学和降压效应。
- 不建议患者同时服用含硝苯地平和含利托那韦的方案。
研究设计与样本
- 基于Simcyp硝苯地平模型开发三种剂型的PBPK/PD模型,并用已发表数据验证。
- 在患者中评估利托那韦对速释、缓释和控释硝苯地平暴露及收缩压的影响。
主要发现
- 三种剂型硝苯地平PBPK/PD模型成功建立,预测Cmax、AUC、收缩压最大降低幅度和效应-时间曲线下面积均在观测数据0.5–2.0倍范围内。
- 模型模拟显示利托那韦抑制CYP3A4使稳态硝苯地平Cmax升高17.92–48.85倍、AUC升高63.30–84.01倍。
- 合用后收缩压降低>40 mmHg,可能导致严重低血压。
关键数值与推荐
- 利托那韦使硝苯地平稳态Cmax升高17.92–48.85倍、AUC升高63.30–84.01倍。
- 合用后收缩压降低>40 mmHg。
- 模型预测值需在观测数据0.5–2.0倍范围内视为验证通过。
临床怎么用
- 临床应避免硝苯地平与含利托那韦方案同时使用。
- 对使用含利托那韦方案的高血压患者,需关注降压药选择与血压监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Hypertension is a common comorbidity of patients with COVID-19, SARS or HIV infection. Such patients are often concomitantly treated with antiviral and antihypertensive agents, including ritonavir and nifedipine. Since ritonavir is a strong inhibitor of CYP3A and nifedipine is mainly metabolized via CYP3A, the combination of ritonavir and nifedipine can potentially cause drug-drug interactions. This study provides guidance on nifedipine treatment during and after coadministration with ritonavir-containing regimens, using a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) analysis. METHODS: The PBPK/PD models for 3 formations of nifedipine were developed based on the Simcyp nifedipine model and the models were verified using published data. The effects of ritonavir on nifedipine exposure and systolic blood pressure (SBP) were assessed for instant-release, sustained-release and controlled-release formulations in patients. Various nifedipine regimens were investigated when coadministered with or without ritonavir. RESULTS: PBPK/PD models for 3 formulations of nifedipine were successfully established. The predicted maximum concentration (Cmax ), area under plasma concentration-time curve (AUC), maximum reduction in SBP and area under effect-time curve were all within 0.5-2.0-fold of the observed data. Model simulations showed that the inhibitory effect of ritonavir on CYP3A4 increased the Cmax of nifedipine 17.92-48.85-fold and the AUC 63.30-84.01-fold at steady state and decreased the SBP by >40 mmHg. Thus, the combination of nifedipine and ritonavir could lead to severe hypotension. CONCLUSION: Ritonavir significantly affects the pharmacokinetics and antihypertensive effect of nifedipine. It is not recommended for patients to take nifedipine- and ritonavir-containing regimens simultaneously.
引用
- Niu W, Li S, Jin S, et al. Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. Br J Clin Pharmacol. 2020. PMID: 33269470. doi:10.1111/bcp.14684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。